These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33651913)

  • 81. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
    Lamba N; Ott PA; Iorgulescu JB
    JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity.
    Radbill AE; Fiveash JF; Falkenberg ET; Guthrie BL; Young PE; Meleth S; Markert JM
    Cancer; 2004 Aug; 101(4):825-33. PubMed ID: 15305416
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome.
    Wegner RE; Abel S; D'Amico RS; Mehta GU; Sheehan J
    J Neurooncol; 2021 Mar; 152(1):79-87. PubMed ID: 33432380
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Determinants of survival in patients with brain metastases from cutaneous melanoma.
    Staudt M; Lasithiotakis K; Leiter U; Meier F; Eigentler T; Bamberg M; Tatagiba M; Brossart P; Garbe C
    Br J Cancer; 2010 Apr; 102(8):1213-8. PubMed ID: 20372154
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Salvage stereotactic radiosurgery for breast cancer brain metastases: outcomes and prognostic factors.
    Kelly PJ; Lin NU; Claus EB; Quant EC; Weiss SE; Alexander BM
    Cancer; 2012 Apr; 118(8):2014-20. PubMed ID: 21918959
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The Analysis of Trends in Survival for Patients with Melanoma Brain Metastases with Introduction of Novel Therapeutic Options before the Era of Combined Immunotherapy-Multicenter Italian-Polish Report.
    Placzke J; Teterycz P; Quaglino P; Cybulska-Stopa B; Tucci M; Rubatto M; Skora T; Interno V; Rosinska M; Borkowska A; Szumera-Cieckiewicz A; Mandala M; Rutkowski P
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497248
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).
    Samlowski WE; Watson GA; Wang M; Rao G; Klimo P; Boucher K; Shrieve DC; Jensen RL
    Cancer; 2007 May; 109(9):1855-62. PubMed ID: 17351953
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
    Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
    J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Which is the best treatment for melanoma brain metastases? A Bayesian network meta-analysis and systematic review.
    Li C; Li K; Zhong S; Tang M; Shi X; Bao Y
    Crit Rev Oncol Hematol; 2024 Feb; 194():104227. PubMed ID: 38220124
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery.
    Samlowski WE; Majer M; Boucher KM; Shrieve AF; Dechet C; Jensen RL; Shrieve DC
    Cancer; 2008 Nov; 113(9):2539-48. PubMed ID: 18780316
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure.
    Tringale KR; Reiner AS; Sehgal RR; Panageas K; Betof Warner AS; Postow MA; Moss NS
    CNS Oncol; 2023 Mar; 12(1):CNS93. PubMed ID: 36802833
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Melanoma brain metastases: is it time to eliminate radiotherapy?
    White RJ; Abel S; Horne ZD; Lee J; Edington H; Greenberg L; Younes H; Hilton C; Wegner RE
    J Neurooncol; 2020 Aug; 149(1):27-33. PubMed ID: 32556863
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016.
    Brastianos HC; Nguyen P; Sahgal A; Eisenhauer EA; Baetz T; Hanna TP
    JAMA Netw Open; 2020 Jul; 3(7):e208204. PubMed ID: 32663310
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.
    Karz A; Dimitrova M; Kleffman K; Alvarez-Breckenridge C; Atkins MB; Boire A; Bosenberg M; Brastianos P; Cahill DP; Chen Q; Ferguson S; Forsyth P; Glitza Oliva IC; Goldberg SB; Holmen SL; Knisely JPS; Merlino G; Nguyen DX; Pacold ME; Perez-Guijarro E; Smalley KSM; Tawbi HA; Wen PY; Davies MA; Kluger HM; Mehnert JM; Hernando E
    Pigment Cell Melanoma Res; 2022 Nov; 35(6):554-572. PubMed ID: 35912544
    [TBL] [Abstract][Full Text] [Related]  

  • 96. High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy.
    Dercle L; Ammari S; Roblin E; Bigorgne A; Champiat S; Taihi L; Plaian A; Hans S; Lakiss S; Tselikas L; Rouanne M; Deutsch E; Schwartz LH; Gönen M; Flynn J; Massard C; Soria JC; Robert C; Marabelle A
    Eur J Cancer; 2022 Dec; 177():80-93. PubMed ID: 36332438
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases.
    Tétu P; Sirven-Villaros L; Cuzzubbo S; Ursu R; Baroudjian B; Delyon J; Nataf F; De Margerie-Mellon C; Allayous C; Lefevre W; Carpentier AF; Lebbé C
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32947841
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control.
    Sheehan JP; Sun MH; Kondziolka D; Flickinger J; Lunsford LD
    J Neurosurg; 2003 Feb; 98(2):342-9. PubMed ID: 12593621
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases.
    Moyers JT; Chong EG; Peng J; Tsai HHC; Sufficool D; Shavlik D; Nagaraj G
    Cancer Med; 2021 Feb; 10(4):1201-1211. PubMed ID: 33484100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.